Heterocyclic Compounds

Matches 1 - 50 out of 30,886	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/082724A1	PIM KINASE INHIBITOR IN COMBINATION WITH KRAS INHIBITOR It relates to the combination of PIM kinase inhibitor and a KRAS inhibitor for use in treating cancer, in a subject in need thereof. Also provided are compositions or kits comprising same. Furthermore, it also relates to a PIM kinase inh...
WO/2024/084447A2	AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Compounds of formula (I) and an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3 and W, are as defined in the specification, are usef...
WO/2024/085695A1	NOVEL ALTIRATINIB DERIVATIVE, MANUFACTURING METHOD THEREFOR, AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SKIN PIGMENTATION The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
WO/2024/082917A1	CRYSTAL FORM A OF BUPIVACAINE-MELOXICAM SALT, SINGLE CRYSTAL THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a crystal form A of bupivacaine-meloxicam salt, a single crystal thereof, a preparation method therefor and a use thereof. An X-ray powder diffraction pattern of the crystal form A of the bupivacaine-meloxicam salt has char...
WO/2024/086717A2	HETEROARYL ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A The present disclosure provides compounds of the formulae herein (e.g., Formula (I) and (V)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, a...
WO/2024/086252A1	NOVEL ATP-SENSITIVE POTASSIUM CHANNEL POTENTIATORS, THEIR PREPARATION AND USE The present disclosure relates to compounds of general formula (I) or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, methods for their preparation, the use of said compounds for use as a medicament, and their use in ...
WO/2024/085699A1	COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF The present disclosure provides a compound of a specific chemical structure, an optical isomer, stereoisomer, isotopic variant, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof, which has excellent activity in te...
WO/2024/084360A1	PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS The present invention relates to compounds of Formula A, and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such proce...
WO/2024/083137A1	FUSED HETEROCYCLIC AROMATIC HYDROCARBON COMPOUNDS, AND COMPOSITION AND USE THEREOF Provided in the present invention are novel fused heterocyclic aromatic hydrocarbon compounds or pharmaceutically acceptable salts thereof, a pharmaceutical composition containing same, and the use of same as a KIF18A inhibitor in preven...
WO/2024/084186A1	TREATMENT OF LEISHMANIASIS The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
WO/2024/083237A1	SUBSTITUTED HETEROARYL BICYCLIC COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
WO/2024/086705A2	BICYCLIC ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A The present disclosure provides compounds of formulae herein (e.g., Formula (I- a) and (I-b)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, ...
WO/2024/083886A1	RNA-BINDING MOLECULES WITH A SMALL CORE SCAFFOLD (R-SCORE) AND USES THEREOF The present invention relates to novel RNA-binding azetidine compounds of general formula (I) and stereoisomeric forms, hydrates, solvates and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing s...
WO/2024/078436A1	HETEROCYCLIC PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF The present disclosure discloses a compound having formula (I) or a pharmaceutically acceptable salt thereof which acts as a USP1 inhibitor, a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt the...
WO/2024/080361A1	IMIDAZOLE DERIVATIVE The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
WO/2024/080655A1	COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING SAME, AND ELECTRONIC DEVICE HAVING SAME The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
WO/2024/081345A1	BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS Novel PI3K inhibitors of the general formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, formula (1), wherein R1 to...
WO/2024/081927A1	COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
WO/2024/078620A1	NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
WO/2024/080788A1	NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a novel tricycle derivative compound and uses thereof, more specifically to a novel tricycle derivative compound having inhibitory activity for methionine adenosyltransferase 2A (MAT2A) and uses thereof.
WO/2024/059525A3	COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANAPLASTIC LYMPHOMA KINASE AND ROS1 KINASE Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for anaplastic lymphoma kinase (ALK) an...
WO/2024/077650A1	SALT FORM OF COMPOUND HAVING SUBSTITUTED SULFONYLUREA RING AND CRYSTAL FORM THEREOF The present invention provides a salt form of a compound having a substituted sulfonylurea ring and a crystal form thereof, as well as a specific crystal form A thereof, and further provides a use thereof in the preparation of a drug for...
WO/2024/050019A3	PROCESS FOR PREPARING FORM III OF RITONAVIR The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising ...
WO/2024/076670A2	TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
WO/2024/074848A1	PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; MPL comprises a SARS-CoV-2 main protease ligand, X comprises a divalent exit vector; Xi comprises a divalent exit vector; a and b are independently ...
WO/2024/076891A1	POLO LIKE KINASE 4 INHIBITORS Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
WO/2024/076672A1	HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
WO/2024/074611A1	PRMT5 INHIBITORS The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
WO/2024/077057A1	PHENYL OXY AMIDE KINASE INHIBITORS Compounds having activity as kinase inhibitors are provided. The compounds have Structure (I), or a stereoisomer, tautomer, or salt thereof, wherein, R1, R3, and m are as defined herein. Methods associated with preparation and use of suc...
WO/2024/075815A1	8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
WO/2024/075051A1	HSD17B13 INHIBITORS AND/OR DEGRADERS Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
WO/2024/076674A1	HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
WO/2024/074414A1	HERBICIDAL IMIDAZOLE COMPOUNDS The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein Q, R2, R3 and U are as defined herein. The invention further relates to herbicidal compositions which comprise a...
WO/2024/076155A1	NOVEL COMPOUND AS YEATS DOMAIN INHIBITOR The present invention evaluated a method for producing a novel ENL/AF9 YEATS domain inhibitor, wherein the ENL/AF9 YEATS domain inhibition ability of a compound made through the production method was evaluated, and the novel compound was...
WO/2024/077216A1	CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS The disclosure is directed to compounds of Formula I (I). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
WO/2024/068950A1	MICROBIOCIDAL PYRAZOLE DERIVATIVES A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
WO/2024/067802A1	PROTEIN TYROSINE PHOSPHATASE INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF The present application provides a compound represented by formula (I), a preparation method therefor, and use thereof. The compound provided in the present application can be used for inhibiting the activity of protein tyrosine phosphat...
WO/2024/068948A1	NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormalit...
WO/2024/068655A1	FUNGICIDAL COMPOSITIONS A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of pl...
WO/2024/071439A1	FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME The present invention provides a novel compound that has an STAT6 inhibitory effect and is efficacious in treating inflammatory diseases and allergic diseases such as atopic dermatitis. A compound represented by general formula (I) and h...
WO/2024/067818A1	CHIMERIC COMPOUND USED FOR TARGETED DEGRADATION OF BCL-2 PROTEIN, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF The present disclosure relates to a chimeric compound used for targeted degradation of a BCL-2 protein, a preparation method therefor, and pharmaceutical application thereof. Specifically, the present disclosure relates to a heterocyclic...
WO/2024/069378A1	NOVEL COMPOUNDS FOR THE TREATMENT OF MAMMALIAN INFECTIONS The present invention provides novel compounds of Formula (I) or its pharmaceutically acceptable salts. The novel compounds reported in present invention are suitable for the treatment against infection caused by Gram-positive bacteria.
WO/2024/068520A1	3-(HETERO)ARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
WO/2024/071398A1	ABHD6 ANTAGONIST The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
WO/2024/073587A1	N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Compounds and methods for inhibiting Nrf2 by activating KEAP1.
WO/2024/069634A1	MICROTUBULE TARGETING AGENTS The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
WO/2024/072794A1	PYRIDINE CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
WO/2024/073426A1	1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
WO/2024/073502A1	HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
WO/2024/069592A1	N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a com...

Matches 1 - 50 out of 30,886	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >